These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31241440)

  • 1. Overcoming Cancer Cell Drug Resistance by a Folic Acid Targeted Polymeric Conjugate of Buthionine Sulfoximine.
    Cilurzo F; Cristiano MC; Da Pian M; Cianflone E; Quintieri L; Paolino D; Pasut G
    Anticancer Agents Med Chem; 2019; 19(12):1513-1522. PubMed ID: 31241440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
    Pasut G; Canal F; Dalla Via L; Arpicco S; Veronese FM; Schiavon O
    J Control Release; 2008 May; 127(3):239-48. PubMed ID: 18346806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
    Lewis-Wambi JS; Kim HR; Wambi C; Patel R; Pyle JR; Klein-Szanto AJ; Jordan VC
    Breast Cancer Res; 2008; 10(6):R104. PubMed ID: 19061505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
    Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
    Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macromolecular bipill of gemcitabine and methotrexate facilitates tumor-specific dual drug therapy with higher benefit-to-risk ratio.
    Das M; Jain R; Agrawal AK; Thanki K; Jain S
    Bioconjug Chem; 2014 Mar; 25(3):501-9. PubMed ID: 24506698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice.
    Reliene R; Schiestl RH
    Carcinogenesis; 2006 Feb; 27(2):240-4. PubMed ID: 16162646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of buthionine sulfoximine on the chlorin e6-based photodynamic treatment of cancer cells.
    Lee HM; Kim DH; Lee HL; Cha B; Kang DH; Jeong YI
    Arch Pharm Res; 2019 Nov; 42(11):990-999. PubMed ID: 31482490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine.
    Dubey RD; Alam N; Saneja A; Khare V; Kumar A; Vaidh S; Mahajan G; Sharma PR; Singh SK; Mondhe DM; Gupta PN
    Int J Pharm; 2015 Aug; 492(1-2):80-91. PubMed ID: 26165611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells.
    Gana CC; Hanssen KM; Yu DMT; Flemming CL; Wheatley MS; Conseil G; Cole SPC; Norris MD; Haber M; Fletcher JI
    Biochem Pharmacol; 2019 Oct; 168():237-248. PubMed ID: 31302132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P; Loh SY; Kelland LR; Harrap KR
    Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 2-methoxyestradiol, buthionine sulfoximine and hydrogen peroxide on the viability of renal carcinoma cell lines (ACHN and ACVB).
    Hirai Y; Kawabe N; Tsuda Y; Miyamoto S; Iwakawa S
    Biol Pharm Bull; 2006 May; 29(5):1064-7. PubMed ID: 16651749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
    Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
    Chem Biol Interact; 1998 Apr; 111-112():277-305. PubMed ID: 9679561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nrf2 mediates the resistance of human A549 and HepG2 cancer cells to boningmycin, a new antitumor antibiotic, in vitro through regulation of glutathione levels.
    Zhang HX; Chen Y; Xu R; He QY
    Acta Pharmacol Sin; 2018 Oct; 39(10):1661-1669. PubMed ID: 30287928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine.
    Maeda H; Hori S; Ohizumi H; Segawa T; Kakehi Y; Ogawa O; Kakizuka A
    Cell Death Differ; 2004 Jul; 11(7):737-46. PubMed ID: 15002036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
    Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
    Pigment Cell Res; 1997 Aug; 10(4):236-49. PubMed ID: 9263331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma.
    Palomares T; Bilbao P; del Olmo M; Castro B; Calle Y; Alonso-Varona A
    Melanoma Res; 1999 Jun; 9(3):233-42. PubMed ID: 10465578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms.
    Alexander RL; Greene BT; Torti SV; Kucera GL
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):15-21. PubMed ID: 15789226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PKCĪ“ sensitizes neuroblastoma cells to L-buthionine-sulfoximine and etoposide inducing reactive oxygen species overproduction and DNA damage.
    Marengo B; De Ciucis C; Ricciarelli R; Passalacqua M; Nitti M; Zingg JM; Marinari UM; Pronzato MA; Domenicotti C
    PLoS One; 2011 Feb; 6(2):e14661. PubMed ID: 21326872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of 6-(methylsulfinyl)hexyl isothiocyanate for sensitization of tumor cells to antitumor agents in combination therapies.
    Yamaguchi H; Kidachi Y; Kamiie K; Noshita T; Umetsu H; Fuke Y; Ryoyama K
    Biochem Pharmacol; 2013 Aug; 86(4):458-68. PubMed ID: 23791871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.